Wyeth Protonix I.V. Indicated As Second-Line Therapy After Oral Pantoprazole
Executive Summary
Wyeth-Ayerst's intravenous proton pump inhibitor Protonix will be launched in mid-April as a second-line alternative to Protonix (pantoprazole) tablets.
You may also be interested in...
Wyeth Zosyn Inventory Allocation Program Likely To Last Through 2002
Wyeth is suspending production of Pipracil (piperacillin) in order to increase supplies of the piperacillin/tazobactam combination agent Zosyn, the company said in a Feb. 27 letter to the trade
Wyeth Zosyn Inventory Allocation Program Likely To Last Through 2002
Wyeth is suspending production of Pipracil (piperacillin) in order to increase supplies of the piperacillin/tazobactam combination agent Zosyn, the company said in a Feb. 27 letter to the trade
Wyeth Protonix I.V. "Coming Soon" Promotions Challenged By FDA
FDA is challenging Wyeth-Ayerst's "Coming Soon" promotions for Protonix I.V. on the grounds that they failed to disclose "facts that are material" to the status of the intravenous proton pump inhibitor.